Clinical Trials Browser

Withdrawn × Fallopian Tube Neoplasms × Bevacizumab × Clear all

NCT04510584 2023-06-06

Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

Phase 2 Withdrawn

Fallopian Tube Neoplasms

NCT01131039 2013-12-20

Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms